|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei LY, Kong M, Zhang Z and Zhang XC:
Breast metastasis of gastric signet-ring cell carcinoma. J Zhejiang
Univ Sci B. 18:1026–1030. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choudhery S, Xiao L and Zingula S: Review
of nonmammary metastases to the breast: Imaging and clinical
presentation. Curr Probl Diagn Radiol. 50:495–498. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu C, Ding L, Sun B and Wu S: Bilateral
breast adenocarcinomas with EML4-ALK fusion in a patient with
multiple metastases successfully treated with crizotinib: Is lung
the primary site? Onco Targets Ther. 9:3589–3593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lei Y, Lei Y, Shi X and Wang J: EML4-ALK
fusion gene in non-small cell lung cancer. Oncol Lett. 24:2772022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Golding B, Luu A, Jones R and
Viloria-Petit AM: The function and therapeutic targeting of
anaplastic lymphoma kinase (ALK) in non-small cell lung cancer
(NSCLC). Mol Cancer. 17:522018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirsch FR, Suda K, Wiens J and Bunn PA Jr:
New and emerging targeted treatments in advanced non-small-cell
lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rakha EA, Alsaleem M, ElSharawy KA, Toss
MS, Raafat S, Mihai R, Minhas FA, Green AR, Rajpoot NM, Dalton LW
and Mongan NP: Visual histological assessment of morphological
features reflects the underlying molecular profile in invasive
breast cancer: A morphomolecular study. Histopathology. 77:631–645.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hussaini HM, Seo B and Rich AM:
Immunohistochemistry and Immunofluorescence. Methods Mol Biol.
2588:439–450. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schneider C, Fehr MK, Steiner RA, Hagen D,
Haller U and Fink D: Frequency and distribution pattern of distant
metastases in breast cancer patients at the time of primary
presentation. Arch Gynecol Obstet. 269:9–12. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bachman J: Reverse-transcription PCR
(RT-PCR). Methods Enzymol. 530:67–74. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang Z, Wang W, Hu Q, Zhou P, Zhang Y,
Tang Y, Wu Q, Fu Y, Li X, Shao Y and Jiang L: Pulmonary large cell
carcinoma with neuroendocrine morphology shows genetic similarity
to large cell neuroendocrine carcinoma. Diagn Pathol. 17:262022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sui X, Jiang W, Chen H, Yang F, Wang J and
Wang Q: Validation of the stage groupings in the eighth edition of
the TNM classification for lung cancer. J Thorac Oncol.
12:1679–1686. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cocks K, Wells JR, Johnson C, Schmidt H,
Koller M, Oerlemans S, Velikova G, Pinto M, Tomaszewski KA,
Aaronson NK, et al: Content validity of the EORTC quality of life
questionnaire QLQ-C30 for use in cancer. Eur J Cancer. 178:128–138.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee SK, Kim WW, Kim SH, Hur SM, Kim S,
Choi JH, Cho EY, Han SY, Hahn BK, Choe JH, et al: Characteristics
of metastasis in the breast from extramammary malignancies. J Surg
Oncol. 101:137–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Babu KS, Roberts F, Bryden F, McCafferty
A, Downer P, Hansell DT, Jones R and Milroy R: Metastases to breast
from primary lung cancer. J Thorac Oncol. 4:540–542. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao X, Chen P, Agyekum EA, Zhang Q, Qian
X, Wu T, Chambers KH and Yin L: Lung cancer with breast metastasis:
A case report and review of the literature. J Int Med Res.
51:30006052311882872023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J, Liu YS, Liu DD and Li XL: Metastasis
to breast from primary lung cancer: A rare case report. Asian J
Surg. 45:2562–2563. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Wei H, Li S, Wu P and Mao X: The
role of progesterone receptors in breast cancer. Drug Des Devel
Ther. 16:305–314. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ni YB, Tsang JYS, Shao MM, Chan SK, Cheung
SY, Tong J, To KF and Tse GM: GATA-3 is superior to GCDFP-15 and
mammaglobin to identify primary and metastatic breast cancer.
Breast Cancer Res Treat. 169:25–32. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Robens J, Goldstein L, Gown AM and Schnitt
SJ: Thyroid transcription factor-1 expression in breast carcinomas.
Am J Surg Pathol. 34:1881–1885. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang B, Jiang Y, Li SY, Niu RL, Blasberg
JD, Kaifi JT, Liu G and Wang ZL: Breast metastases from primary
lung cancer: A retrospective case series on clinical,
ultrasonographic, and immunohistochemical features. Transl Lung
Cancer Res. 10:3226–3235. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ji FF, Gao P, Wang JG, Zhao J and Zhao P:
Contralateral breast metastasis from pulmonary adenocarcinoma: Two
cases report and literature review. J Thorac Dis. 4:384–389.
2012.PubMed/NCBI
|
|
25
|
Ali RH, Taraboanta C, Mohammad T, Hayes MM
and Ionescu DN: Metastatic non-small cell lung carcinoma a mimic of
primary breast carcinoma-case series and literature review.
Virchows Arch. 472:771–777. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya
T, Ishida T and Mori M: EML4-ALK fusion transcript is not found in
gastrointestinal and breast cancers. Br J Cancer. 98:1536–1539.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shreenivas A, Janku F, Gouda MA, Chen HZ,
George B, Kato S and Kurzrock R: ALK fusions in the pan-cancer
setting: Another tumor-agnostic target? NPJ Precis Oncol.
7:1012023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ross JS, Ali SM, Fasan O, Block J, Pal S,
Elvin JA, Schrock AB, Suh J, Nozad S, Kim S, et al: ALK fusions in
a wide variety of tumor types respond to anti-ALK targeted therapy.
Oncologist. 22:1444–1450. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
AACR Project GENIE Consortium, . AACR
project GENIE: Powering precision medicine through an international
consortium. Cancer Discov. 7:818–831. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Narod SA: Which genes for hereditary
breast cancer? N Engl J Med. 384:471–473. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu C, Hart SN, Gnanaolivu R, Huang H, Lee
KY, Na J, Gao C, Lilyquist J, Yadav S, Boddicker NJ, et al: A
population-based study of genes previously implicated in breast
cancer. N Engl J Med. 384:440–451. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Breast Cancer Association Consortium, .
Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C,
Wahlström C, Pooley KA, Parsons MT, Fortuno C, et al: Breast cancer
risk genes-association analysis in more than 113,000 women. N Engl
J Med. 384:428–439. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maddalo D, Manchado E, Concepcion CP,
Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, Rekhtman N,
de Stanchina E, et al: In vivo engineering of oncogenic chromosomal
rearrangements with the CRISPR/Cas9 system. Nature. 516:423–427.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoshida T, Oya Y, Tanaka K, Shimizu J,
Horio Y, Kuroda H, Sakao Y, Hida T and Yatabe Y: Differential
crizotinib response duration among ALK fusion variants in
ALK-positive non-small-cell lung cancer. J Clin Oncol.
34:3383–3389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang SS, Nagasaka M, Zhu VW and Ou SHI:
Going beneath the tip of the iceberg. Identifying and understanding
EML4-ALK variants and TP53 mutations to optimize treatment of ALK
fusion positive (ALK+) NSCLC. Lung Cancer. 158:126–136. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tabbò F, Muscarella LA, Gobbini E,
Trombetta D, Castellana S, Rigutto A, Galetta D, Maiello E,
Martelli O, Tiseo M, et al: Detection of ALK fusion variants by
RNA-based NGS and clinical outcome correlation in NSCLC patients
treated with ALK-TKI sequences. Eur J Cancer. 174:200–211. 2022.
View Article : Google Scholar : PubMed/NCBI
|
